A team of researchers from Osaka University, in cooperation with the Institute for Clinical Research and medical institutes participating in the Kansai Molecular Diagnosis Network for CNS Tumors, conducted the largest-ever retrospective cohort study for Japanese patients with glioblastoma, proposing an underlying prognosis biomarker responsible for the survival difference between two cohorts: an original Japanese cohort and a dataset from The Cancer Genome Atlas.